| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHPSYC.1991.01810250064008 |
| P698 | PubMed publication ID | 1984763 |
| P50 | author | Harrison Pope | Q14948677 |
| Susan L McElroy | Q56816544 | ||
| James I Hudson | Q102214732 | ||
| Paul E. Keck | Q111738411 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 62-68 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Valproate in the treatment of acute mania. A placebo-controlled study | |
| P478 | volume | 48 |
| Q61886048 | A History of the Pharmacological Treatment of Bipolar Disorder |
| Q42164465 | A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania |
| Q52932623 | A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. |
| Q41669830 | A naturalistic comparison of adverse effects between slow titration and loading of divalproex sodium in psychiatric inpatients |
| Q37442060 | A new role for the P2Y-like GPR17 receptor in the modulation of multipotency of oligodendrocyte precursor cells in vitro |
| Q40615953 | A pilot study of loading versus titration of valproate in the treatment of acute mania |
| Q34106683 | A review of randomized, controlled clinical trials in acute mania |
| Q35236966 | Acute and long-term treatment of mania. |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q34205852 | Adolecsent mania, EEG abnormality and response to anticonvulsants: a three - year follow-up study |
| Q67991531 | Alopecia and mood stabilizers: two case reports |
| Q37721742 | An open-label pilot study of divalproex sodium for posttraumatic stress disorder related to childhood abuse |
| Q35664266 | Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians |
| Q35236134 | Anticonvulsant drugs in bipolar disorder. |
| Q36228209 | Anticonvulsants in anxiety disorders |
| Q37524484 | Anticonvulsants in bipolar disorders: current research and practice and future directions |
| Q36407359 | Anticonvulsants in the treatment of bipolar mania |
| Q44112140 | Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity |
| Q36827444 | Antiepileptic drugs and mood stability. |
| Q35904830 | Antiepileptic drugs in the treatment of anxiety disorders: role in therapy |
| Q37524494 | Antipsychotic agents in the treatment of bipolar mania |
| Q34110848 | Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials |
| Q44393866 | Assessment of treatment response in mania: commentary and new findings |
| Q45265949 | Augmentation of valproate with lithium in a case of rapid cycling affective disorder |
| Q34547920 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q57244668 | Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder |
| Q36165238 | Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials |
| Q41461251 | Bipolar mood disorders in the elderly. |
| Q33768230 | Bipolarity in children |
| Q51934433 | Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. |
| Q46573427 | Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat. |
| Q34809427 | Class effect of pharmacotherapy in bipolar disorder: fact or misbelief? |
| Q30961090 | Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials |
| Q57244765 | Combining Lithium and Sodium Valproate for Bipolar Disorder |
| Q34387550 | Comparative efficacy and tolerability of drug treatments for bipolar disorder |
| Q40866452 | Continuation and maintenance pharmacotherapy for unipolar and bipolar mood disorders. |
| Q77909043 | Divalproex in posttraumatic stress disorder: an open-label clinical trial |
| Q43582636 | Divalproex sodium in sex offenders with bipolar disorders and comorbid paraphilias: an open retrospective study |
| Q39410022 | Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression |
| Q34455825 | Double‐blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder |
| Q30912418 | Drug therapy of acute manias. A retrospective data analysis of inpatients from 1997 to 1999 |
| Q40850874 | Drug treatment of mania: a critical review |
| Q41727635 | Early childhood attention deficit hyperactivity disorder predicts poorer response to acute lithium therapy in adolescent mania |
| Q53591626 | Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. |
| Q51600062 | Effect of infusion duration on valproate pharmacokinetics. |
| Q37366007 | Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial |
| Q34634154 | Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. |
| Q72561737 | Effects of chronic treatment with valproate on serotonin-1A receptor binding and function |
| Q42633478 | Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics |
| Q35101178 | Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects |
| Q34034322 | Efficacy and tolerability of injectable sodium valproate in patients with mania |
| Q24601815 | Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials |
| Q38012647 | Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry |
| Q43194171 | Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open-label comparative study |
| Q43193438 | Exploring differential prescribing between anti-epileptic drugs in epilepsy patients with a history of mood disorders |
| Q46984808 | Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials |
| Q36875598 | Extended-release formulations in epilepsy |
| Q53080275 | Factors modifying drug and placebo responses in randomized trials for bipolar mania. |
| Q34415724 | Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine |
| Q36568973 | How assess drugs in the treatment of acute bipolar mania? |
| Q55475244 | Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. |
| Q33518859 | Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. |
| Q36099541 | Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder |
| Q36060748 | Latest therapies for bipolar disorder. Looking beyond lithium |
| Q33529314 | Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis |
| Q78650845 | Limits of the applicability and generalizability of drug trials in mania |
| Q34270519 | Lithium revisited. |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q41177967 | Long term treatment of bipolar disorder |
| Q34340984 | Management of psychiatric disorders in patients infected with human immunodeficiency virus |
| Q36284465 | Management options for bipolar disorder in children and adolescents |
| Q92206076 | Mania in elderly people |
| Q36119897 | Mood stabilization in the treatment of bipolar disorder: focus on quetiapine |
| Q36031634 | Mood stabilizer psychopharmacology |
| Q77783228 | Mood stabilizers and anticonvulsants |
| Q37857918 | Multisite international collaborative clinical trials in mania |
| Q35219695 | Naturalistic evaluation of inpatient treatment of mania in a private Brazilian psychiatric hospital |
| Q36687844 | Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder |
| Q35673095 | New anticonvulsant medication uses in bipolar disorder |
| Q35872066 | New medication treatment options for bipolar disorders |
| Q74242303 | On defining 'mood stabilizer' |
| Q35901880 | Optimizing treatment in social phobia: a review of treatment resistance. |
| Q34052819 | Pharmacologic agents for the treatment of acute bipolar mania. |
| Q73628833 | Pharmacologic loading in the treatment of acute mania |
| Q34508138 | Pharmacologic treatment of geriatric mania |
| Q36936379 | Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials |
| Q33895456 | Placebo effect in randomized, controlled studies of acute bipolar mania and depression |
| Q40636834 | Placebo effects in psychiatry. |
| Q30462823 | Predictive animal models of mania: hits, misses and future directions |
| Q51959383 | Principles of effectiveness trials and their implementation in VA Cooperative Study #430: 'Reducing the efficacy-effectiveness gap in bipolar disorder'. |
| Q41060420 | Psychiatric illnesses in the elderly: a review |
| Q60439992 | Psychiatric uses of antiepileptic treatments |
| Q29998990 | Psychopharmacological Agents |
| Q24643545 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder |
| Q37058576 | Pure and mixed manic subtypes: a review of diagnostic classification and validation |
| Q36177621 | Rapid cycling bipolar disorder: clinical characteristics and treatment options |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q80967183 | Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview |
| Q35036680 | Redefining mood stabilization |
| Q35611041 | Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system |
| Q51934399 | Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. |
| Q43667540 | Retrospective analysis of serum valproate levels and need for an antidepressant drug |
| Q26853509 | Review of pharmacological treatment in mood disorders and future directions for drug development. |
| Q33755661 | Role of extended release quetiapine in the management of bipolar disorders |
| Q38584632 | Safety and tolerability of anticonvulsant medication in bipolar disorder |
| Q36446899 | Safety and tolerability of mood-stabilising anticonvulsants in the elderly |
| Q37202889 | Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. |
| Q55007210 | Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach? |
| Q42286828 | Sodium valproate in the treatment of behavioral disturbance in dementia |
| Q79867012 | Somatic treatment of bipolar disorder in children and adolescents |
| Q36691749 | Spectrum of effectiveness of valproate in neuropsychiatry |
| Q68145845 | Stability of plasma γ-aminobutyric acid with time in healthy controls |
| Q37858609 | Study design and patient characteristics and outcome in acute mania clinical trials |
| Q34547500 | Suicidality and divalproex sodium: analysis of controlled studies in multiple indications |
| Q36481051 | Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q33664736 | The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders |
| Q34531273 | The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania |
| Q34606256 | The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania |
| Q34116326 | The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues |
| Q37292350 | The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges. |
| Q28744504 | The effectiveness of anticonvulsants in psychiatric disorders |
| Q38132709 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study |
| Q38774143 | The efficacy of valproate, lamotrigine and gabapentin in bipolar disorder; review of double-blind controlled studies |
| Q40950978 | The emerging role of valproate in bipolar disorder and other psychiatric disorders |
| Q44016458 | The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania |
| Q36128822 | The management of bipolar disorder in primary care: a review of existing and emerging therapies |
| Q37605774 | The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice |
| Q33921196 | The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate. |
| Q35512812 | The natural history and treatment of child and adolescent affective disorders |
| Q33809257 | The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder |
| Q73727431 | The relatively good prognosis of bipolar disorders in a Turkish bipolar clinic |
| Q52030606 | The role of psychopharmacology on an acute adolescent inpatient unit. |
| Q36606791 | The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials |
| Q42164457 | Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials |
| Q40618489 | Treatment approaches for acute mania |
| Q40442918 | Treatment of Bipolar Disorder in Children and Adolescents |
| Q39287194 | Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice? |
| Q35965556 | Treatment of acute mania--from clinical trials to recommendations for clinical practice |
| Q40866426 | Treatment of acute mania. |
| Q36162402 | Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder |
| Q33364302 | Treatment of bipolar disorder: a systematic review of available data and clinical perspectives |
| Q48568036 | Use of polypharmacy and self-reported mood in outpatients with bipolar disorder |
| Q35142736 | Valproate |
| Q22252976 | Valproate for acute mood episodes in bipolar disorder |
| Q34210138 | Valproate in acute mania - a controlled study. |
| Q34264093 | Valproate in acute mania: is our practice evidence based? |
| Q73628831 | Valproate treatment and the risk of hyperandrogenism and polycystic ovaries |
| Q52041607 | Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. |
| Q46848333 | Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder |
| Q33922097 | Valproic acid use in psychiatry: issues in treating women of reproductive age. |
| Q34622357 | What makes a drug a primary mood stabilizer? |
| Q36068766 | Women are not the same as men: specific clinical issues for female patients with bipolar disorder |
Search more.